Physician profile
Stephen Browne
NPI 1306808845
$17,223.01
in general payments reported to CMS, 2019-2025
50 companies · $1,785 in 2025
The $1,785 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,520 · 2020: $2,695 · 2021: $2,749 · 2022: $2,696 · 2023: $2,680 · 2024: $2,098 · 2025: $1,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,498 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,497.79 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,579.88 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $1,521.51 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,468.96 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,201.64 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $1,201.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,022.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Daiichi Sankyo INC. | $882.32 | 2019-2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $795.20 | 2019-2025 | Jardiance, Ofev |
| Janssen Pharmaceuticals, INC | $785.81 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $638.37 | 2019-2025 | |
| Amarin Pharma, INC. | $578.82 | 2019-2021 | |
| Amgen INC. | $533.37 | 2019-2025 | Repatha, Otezla, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $523.01 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $505.56 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $466.14 | 2019-2023 | Verquvo, Janumet, Belsomra |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Browne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.